Pangen Biotech Inc. Logo

Pangen Biotech Inc.

Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.

222110 | KO

Overview

Corporate Details

ISIN(s):
KR7222110009
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 신원로 306, 2동 4층(원천동 영통이노플렉스) , 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pangen Biotech Inc. is a global biotechnology company specializing in the research, development, and manufacturing of biologics. The company's core business focuses on developing and commercializing high-growth biosimilar products, including Erythropoietin (EPO) and Aflibercept. Leveraging its patented platform technology centered on Chinese Hamster Ovary (CHO) cell lines, Pangen Biotech also provides comprehensive Contract Development and Manufacturing Organization (CDMO) services to other biopharmaceutical firms. The company, part of the Huons Group, aims to supply both domestic and international markets with its biologics, reagents, and development services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 77.4 KB
2025-08-20 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 11.0 KB
2025-08-20 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.5 MB
2025-08-13 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.2 MB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-05-20 00:00
Share Issue/Capital Change
전환가액의조정
Korean 17.3 KB
2025-05-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 92.5 KB
2025-05-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-05-12 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.8 KB
2025-05-02 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 40.9 KB
2025-04-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB

Automate Your Workflow. Get a real-time feed of all Pangen Biotech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pangen Biotech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pangen Biotech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.